AIM ImmunoTech Inc. (AIM), an immuno-pharma company, announced that the final subject have received their first dose in the Phase 2 DURIPANC clinical trial evaluating its lead investigational drug, Ampligen (rintatolimod), in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, Imfinzi (Durvalumab), for the treatment of metastatic pancreatic cancer.
The company plans to use the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer.
DURIPANC is an investigator-initiated, exploratory, open-label, single-centre Phase 2 study. The clinical trial is a joint collaboration between AIM, AstraZeneca and Erasmus Medical Centre in the Netherlands.
The primary endpoint of the trial is clinical benefit rate, and the secondary objectives include assessing overall survival (OS) and progression-free survival (PFS); exploring immune monitoring using available tissue biopsies and peripheral immune profiling; and assessing quality of life.
With this final dosing completed, primary endpoint analysis is anticipated to begin in December 2026, and topline results in the first quarter of 2027.
Analysis of secondary endpoints is expected to begin in June 2027, or 49 weeks after the final subject received their first dose.
Notably, DURIPANC is a follow-up to the AIM/Erasmus Medical Centre Named Patient Program utilising Ampligen as a monotherapy in late-stage pancreatic cancer, in which data demonstrated improvements in survival, particularly when stratified by biomarkers.
AIM has traded between $0.21 and $19.73 over the last year. The stock closed Thursday's trade (June 18, 2026) at $0.38, down 5.03%.
In the pre-market, AIM is down 2.96% at $0.37.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.